Who are cyclosporine ophthalmic emulsion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, CYCLOSPORINE VS INFLIXIMAB, reducing Tacrolimus, Tacrolimus sustained-release capsule, switched from Prograf® to Envarsus®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclosporine-ophthalmic-emulsion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

cyclosporine ophthalmic emulsion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

cyclosporine ophthalmic emulsion (cyclosporine ophthalmic emulsion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: immunosuppressant. Area: Ophthalmology.

phase 3 immunosuppressant calcineurin Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

cyclosporine ophthalmic emulsion (cyclosporine ophthalmic emulsion) — Vanderbilt-Ingram Cancer Center. Cyclosporine ophthalmic emulsion works by suppressing the immune system to prevent rejection of transplanted corneal tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cyclosporine ophthalmic emulsion TARGET	cyclosporine ophthalmic emulsion	Vanderbilt-Ingram Cancer Center	phase 3	immunosuppressant	calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)
reducing Tacrolimus	reducing Tacrolimus	Rabin Medical Center	marketed	Calcineurin inhibitor (dose optimization strategy)	Calcineurin/FKBP12 complex
Tacrolimus sustained-release capsule	Tacrolimus sustained-release capsule	Astellas Pharma China, Inc.	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
switched from Prograf® to Envarsus®	switched from Prograf® to Envarsus®	University Hospital, Limoges	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (immunosuppressant class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
DH Bio Co., Ltd. · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
Palvella Therapeutics, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University of California, San Francisco · 1 drug in this class
Vanderbilt-Ingram Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cyclosporine ophthalmic emulsion — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclosporine-ophthalmic-emulsion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab